Carmat, which survived a cash crunch in mid-October, said it had generated annual revenue of 2.8 million euros.

This corresponds to the sale of 17 of its Aeson prostheses, including 11 in the last quarter of 2023, confirming it accelerated the pace of implants.

It also said it sees sales between 14 million and 20 million euros in 2024.

The company confirmed its previously announced target to increase its manufacturing capacity to 500 hearts per year from early 2024, with the opening of a second production facility in Bois-d'Arcy.

($1 = 0.9123 euros)

(Reporting by Sudip Kar-Gupta in Paris, Michal Aleksandrowicz in Gdansk; Editing by Edmund Klamann)